Is 'off-protocol' chemotherapy for androgen-independent carcinoma of prostate warranted?

Hematology/Oncology Clinics of North America

Volumn 10, Issue 3, 1996, Pages 749-768

  Mani, S ^a   Vogelzang, N J ^a  

^a SECTION OF HEMATOLOGY ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTRAMUSTINE PHOSPHATE; FLUOROURACIL; GALLIUM NITRATE; IFOSFAMIDE; KETOCONAZOLE; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW;

EID: 0029952543     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70365-8     Document Type: Article

References (105)

1. F.L. Abele J.D. Wilkes L. Divers Oral cyclophosphamide (CTX) for hormone refractory prostate cancer (HRPC) [abstract 646] Proc Am Soc Clin Oncol 1995 243
2. S.E. Aitken S.D. Huan M. Adams Epirubicin plus cisplatin in hormone-refractory prostate cancer [abstract 753] Proc Am Soc Clin Oncol 1993 241
3. R.J. Amato C.J. Logothetis F.H. Dexeus Preliminary results of a phase II trial of estramustine and vinblastine for patients with progressive hormone-refractory prostate cancer [abstract 1111] Proc Am Assoc Cancer Res 1991 186
4. O. Atiq B. Lewis Treatment of hormone-refractory prostate adenocarcinoma (HRPA) with estramustine and vinblastine (EV) chemotherapy [abstract 745] Proc Am Soc Clin Oncol 1994 240
5. J.N. Atkins H.B. Muss D.I. Case High dose intravenous 5-fluorouracil (5FU) and oral leucovorin (LV) for hormone refractory advanced prostate cancer (APC) [abstract 734] Proc Am Soc Clin Oncol 1993 237
6. H. Becker U. Otto B. Hoffmann Phase 2 study of long term infusion therapy with MMC in patients with progressive prostate cancer [abstract 419] Proc Am Soc Clin Oncol 1990 419A
7. R.C. Benson Estramustine phosphate: Clinical experience in the United States Update Urooncology Experimental and Therapeutic Progress in Prostate Cancer 1988 Promedica Communications New York 19
8. R.C. Benson Jr Role of estramustine phosphate in the treatment of prostate cancer Estracyt, Scientific Edition 2 1988 H Schafers Utrecht 35 64
9. C.J. Bowden W.D. Figg N. Dawson A phase I/II study of continuous infusion suramin in hormone-refractory prostate cancer. Toxicity and response rate [abstract 624] Proc Am Soc Clin Oncol 14 1995 237
10. L.J. Brandes S.P. Bracken C.W. Ramsey N, N-diethy1-2-[4-(phyelmethy1) phenoxy] ethanamine in combination with cyclophosphamide: An active, low-toxicity regimen for metastatic hormonally responsive prostate cancer J Clin Oncol 13 1995 1398
11. C. Bryan R. Munn J.W. MacDonald Treatment of hormone refractory stage D prostate carcinoma with CHIP (NSC 256927) [abstract 579] Proc Am Soc Clin Oncol 1989 148
12. L. Canobbio D. Guarneri L. Miglietta Carbonation in advanced hormone refractory prostatic cancer patients Eur J Cancer 29A 1993 2094 2096
13. S.K. Carter T.H. Wasserman The chemotherapy of urologic cancer Cancer 36 1975 729
14. J.W. Clark B.A. Chabner Suramin and prostate cancer; where do we go from here? J Clin Oncol 13 1995 2155
15. J. Craig E. Crawford Phase II trial of amonafide in advanced prostate cancer: A Southwest Oncology Group study [abstract 240] Proc Am Soc Clin Oncol 1989 147
16. N.A. Dawson Treatment of progressive metastatic prostate cancer Oncology 7 1993 17
17. F. Dexeus C.J. Logothetis M.L. Samuels Continuous infusion of vinblastine for advanced hormone refractory prostate cancer Cancer Treat Rep 69 1985 885
18. F.H. Dexeus C. Logothetis M. Samuels Phase II study of spirogermanium in metastatic prostate cancer Cancer Treat Rep 70 1986 1129
19. R. Dreicer P. Forest R.D. Williams A phase II study of 5-fluorouracil (5-FU) and alpha interferon in hormone-refractory metastatic prostate cancer [abstract 635] Proc Am Soc Clin Oncol 1992 205
20. A. Drelichman D.H. Decker M. Al-Sarraf M-AMSA in disseminated prostatic carcinoma: A Phase II study Cancer Treat Rep 66 1982 1993
21. M.A. Eisenberger Chemotherapy for Prostatic Carcinoma 1987 NIH Consensus Development Conference Bethesda, MD 105
22. M.A. Eisenberger V.J. Sinibaldi L.M. Reyno Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer J Clin Oncol 13 1995 2174
23. I. Elomaa P. Kellokumpu-Lehtinen S. Rannikko Hormone resistant metastatic prostate cancer: Comparison between estramustine phosphate and low dose epirubicin treatments Eur Urol 19 1991 12
24. A.R. Feinstein D.M. Sosin C.K. Wells The Will Rogers phenomenon: Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer N Engl J Med 312 1985 1604
25. S. Fields H. Burns G. Wilding Evaluating the role of navelbine in hormone-refractory prostate cancer (HRPC): A clinical benefit model [abstract 727] Proc Am Soc Clin Oncol 1994 235
26. P. Folmerz C. Anderstrom A. Eddeland A prospective randomized study comparing epirubincin and medroxyprogesterone acetate (MPA) or estramustine phosphate (EMP) in the treatment of hormone-resistant prostatic cancer Ann Oncol 3 1992 109
27. S.D. Fossa T. Urnes O. Kaalhus Weekly low-dose Adriamycin in hormone-resistant metastatic cancer of the prostate Scand J Urol Nephrol 21 1987 13
28. L.M. Glode E.D. Crawford S. Majeski Sinusoidal floxuridine (FUDR) infusions for treatment of advanced hormone refractory prostate cancer [abstract 784] Proc Am Soc Clin Oncol 1994 250
29. C. Graf-Dobberstein H. Rubben U. Otto Systemic chemotherapy of endocrine-resistant prostate carcinoma with cisplatin and mitomycin: Final results of a prospective multicenter trial Eur Urol 18 1990 132
30. C. Haas A. Smith A. Lee Hormone refractory prostate cancer (HRPC): Phase III treatment with cytoxan (C), interferon alpha 2B(I) and infusional 5-fluorouracil (F) [abstract 669] Proc Am Soc Clin Oncol 1992 214
31. G.R. Hudes R. Greenberg R.L. Krigel Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer J Clin Oncol 11 1992 1754
32. W.G. Jones S.D. Fossa A.V. Bono European Organization on Research to Treat Cancer (EORTC) phase II study of low-dose weekly epirubicin in metastatic prostate cancer Cancer Treat Rep 71 1987 1317
33. P.W. Kantoff P. Bryant C. Block Fourteen day constant infusion of mitoxantrone HCL for hormone refractory carcinoma of the prostate (HRCAP): A pilot dose study finding [abstract 562] Proc Am Soc Clin Oncol 1991 175
34. W.K. Kelly T. Curley C. Leibertz Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancers J Clin Oncol 13 1995 2208
35. W.K. Kelly H. Scher D. Bajorin The contribution of hydrocortisone to the A,89 q observed response proportions of suramin [abstract 710] Proc Am Soc Clin Oncol 1994 231
36. W.K. Kelly H.I. Scher M. Mazumdar Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer J Clin Oncol 11 1993 607
37. W.K. Kelly H.I. Scher M. Mazumdar Suramin and hydrocortisone: Determining drug efficacy in androgen-independent prostate cancer J Clin Oncol 13 1995 2214
38. R. Knopf K. Knopf L. Ganesh Pilot study of low dose weekly mitoxantrone as a single agent in widely metastatic hormone-refractory prostate cancer [abstract 789] Proc Am Soc Clin Oncol 12 1993 250
39. K. Kobayashi E.E. Vokes N.J. Vogelzang Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer J Clin Oncol 13 1995 2196
40. P. Koch G. Bayer J. McGovern Continuous infusion 5-fluorouracil (5FU) and weekly doxorubicin for hormone refractory prostate cancer [abstract 641] Proc Am Soc Clin Oncol 1992 207
41. W. Kreis Current chemotherapy and future directions in research for the treatment of advanced hormone-refractory prostate cancer Cancer Invest 13 1995 296
42. S.A. Loening S. Beckley M.F. Brady Comparison of estramustine phosphate, methotrexate, and cis-platinum in patients with advanced, hormone refractory prostate cancer J Urol 129 1983 1001
43. M. Mahjoubi M. Azalo M. Ghosh Phase II trial of Ifosfamide in the treatment of metastatic hormone-refractory patients with prostatic cancer Cancer Invest 8 1990 477
44. M.M. Mareel G.A. Storma C.H. Dragonett Anti-invasive activity of estramustine on malignant MO4 cells and on DU 145 human prostate carcinoma cells in vitro Cancer Res 48 1986 1842
45. C. Maulard-Durdux S. Delanian B. Dufour M. Housset Pilot study of the oral combination cyclophosphamide (CPM)-VP-16 in hormone refractory prostate cancer (HRPC) [abstract 667] Proc Am Soc Clin Oncol 1995 248
46. E. Mendoza A. Belldegrun E. Landaw Suramin efficacy and toxicity in hormone refractory prostate cancer [abstract 801] Proc Am Soc Clin Oncol 13 1994 254
47. M. Moore S.D. Graham R. Birch Phase II evaluation of mitoguazone in metastatic hormone-resistant prostate cancer: A Southeastern Cancer Study Group trial Cancer Treat Rep 71 1987 89
48. M.J. Moore D. Osoba K. Murphy Use of palliative endpoints to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer J Clin Oncol 12 1995 689
49. G.P. Murphy R.P. Gibbons D.E. Johnson The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation J Urol 121 1979 763
50. J.H. Mydlo J. Michaeli W.D. Heston Expression of basic fibroblast growth factor mRNA in benign prostatic hyperplasia and prostatic carcinoma Prostate 13 1988 241
51. C. Myers M. Cooper C. Stein Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer J Clin Oncol 10 1992 881
52. S. Nuan D. Stewart B. Waterfield 5-fluorouracil (5-FU) and high dose folinic acid (HDFA) for patients with hormone-refractory metastatic prostate cancer [abstract 738] Proc Am Soc Clin Oncol 1993 238
53. C.K. Osborne A. Drelichman D.D. VonHoff Mitoxantrone: Modest activity in a phase II trial in advanced prostate cancer Cancer Treat Rep 67 1983 1133
54. D.P. Petrylak A. Yagoda J. O'Connor Phase II trial of suramin in hormone refractory prostate cancer [abstract 780] Proc Am Soc Clin Oncol 13 1994 249
55. K.J. Pienta J. Lehr Inhibition of prostate cancer growth by estramustine and etoposide: Evidence for interaction at the nuclear matrix J Urol 149 1993 1622 1625
56. K.J. Pienta B.G. Redman M. Hussain A combination of estramustine and etoposide orally may be an effective regimen in the treatment of hormone refractory prostate cancer [abstract 770] Proc Am Soc Clin Oncol 1993 246
57. M. Pollak M. Richard Suramin blockade of insulin like growth factor I-stimulated proliferation of human osteosarcoma cells (published erratum appears in J Natl Cancer Inst 82:1510, 1990) J Natl Cancer Inst 82 1990 1349
58. K. Pummer Epirubicin plus flutamide and orchiectomy in previously untreated advanced prostate cancer Semin Oncol 18 suppl 6 1991 26
59. K. Pummer H. Steltner M. Lehnert Phase III study of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer [abstract 705] Proc Am Soc Clin Oncol 1993 229
60. D. Raghavan Non-hormone chemotherapy for prostate cancer. Principles of treatment and application to the testing of new drugs Semin Oncol 15 1990 371
61. D. Raghavan K. Cox B.S. Pearson Oral cyclophosphamide for the management of hormone-refractory prostate cancer Br J Urol 72 1993 625
62. C. Rangel H. Matzkin M.S. Soloway Experience with weekly doxorubicin (Adriamycin) in hormone-refractory stage D2 prostate cancer Urology 39 1992 577
63. B.L. Rapoport G. Falkson J.I. Raats Suramin in combination with mitomycin C in hormone-resistant prostate cancer. A phase II clinical study Ann Oncol 4 1993 567
64. T.P. Rearden E.J. Small F. Valone Phase II study of mitoxantrone for hormonerefractory metastatic prostate cancer [abstract 688] Proc Am Soc Clin Oncol 1992 218
65. L.M. Reyno M.J. Egorin M.A. Eisenberger Development and validation of a pharmacokinetically based fixed dosing scheme for suramin J Clin Oncol 13 1995 2187
66. A.H. Rossof R.W. Tallery R. Stephens Phase II evaluation of cisdichlorodiammi-neplatinum (II) in advanced malignancies of the genitourinary and gynecologic organs: A Southwest Oncology Group study Cancer Treat Rep 63 1979 1557
67. B. Roth B. Yeap G. Wilding Taxol (NSC 125973) in advanced, hormone-refractory prostate cancer: An ECOG phase II trial [abstract 598] Proc Am Soc Clin Oncol 1992 196
68. S. Saxman R. Ansari R. Drasga Phase II trial of cyclophosphamide versus cyclophosphamide, doxorubicin and methotrexate in hormone-refractory prostate cancer Cancer 15 1991 2488
69. H.I. Scher W.K. Kelly Flutamide withdrawal syndrome: Its impact on clinical trials in hormone resistant prostate cancer J Clin Oncol 11 1993 1566
70. S. Scher C.N. Sternberg Chemotherapy of urologic malignancy Semin Urol 3 1985 329
71. H.I. Scher T. Curley N. Geller Gallium nitrate in prostatic cancer: Evaluation of antitumor activity and effects on bone turnover Cancer Treat Rep 71 1987 887 893
72. H.I. Scher T. Curley N. Geller Trimetrexate in prostatic cancer: Preliminary observations of the use of the prostate specific antigen and acid phosphatase as a marker in measurable hormone refractory disease J Clin Oncol 8 1990 1830
73. H. Scher A. Yagoda T. Ahmad Methylglyoxal bis(guanylhydrazone) MGBG: An active drug in prostatic cancer J Clin Oncol 3 1985 224
74. H. Scher A. Yagoda R. Watson Phase II trial of doxorubicin in bidimensionally measurable prostatic adenocarcinoma J Urol 13 1984 1099
75. J.D. Schmidt W.W. Scott R.P. Gibbons Comparison of procarbazine, imidazolecarbamide and cyclophosphamide in relapsing patients with advanced carcinoma of the prostate J Urol 121 1979 185 189
76. W.W. Scott R.P. Gibbons D.E. Johnson The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate J Urol 116 1976 211
77. A.D. Seidman H.I. Scher D. Petrylak Estramustine and vinblastine: Use of PSA as a clinical end point for hormone refractory prostatic cancer J Urol 147 1992 931
78. A. Sella R. Kilbourne R. Amato A phase II study of ketoconazole (KC) combined with weekly doxorubicin (DOX) in patients (pts) with hormone refractory prostate cancer (PC) results in high response rate [abstract 691] Proc Am Soc Clin Oncol 1992 219
79. E.J. Small S. Srinivas S. Madhavan Use of doxorubicin (D) and dose-escalated cyclophosphamide (C) with granulocyte colony stimulating factor (gCSF) in the treatment of hormone refractory prostate cancer (HRPC) [abstract 648] Proc Am Soc Clin Oncol 1995 243
80. Smith DC, Vogelzang NJ, Day R, et al: Phase I/II trials of high-dose cyclophosphamide with recombinant human granulocyte-macrophage-colony stimulating factor in hormone-refractory prostatic cancer. Submitted, 1995
81. T.J. Smith B.E. Hillner D.M. Neighbors Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small cell lung cancer J Clin Oncol 13 1995 2166
82. M.S. Soloway S. Beckley M.F. Brady A comparison of estramustine phosphate, versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had extensive irradiation to the pelvis or lumbosacral area J Urol 129 1983 56
83. M.S. Soloway J.B. Dekernion R.P. Gibbons Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced hormone refractory previously irradiated carcinoma of the prostate J Urol 125 1981 664
84. T.A. Stamey J.N. Kabalin Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients J Urol 141 1989 1070
85. T.A. Stamey J.N. Kabalin M. Ferrari Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients J Urol 141 1989 1084
86. T.A. Stamey J.N. Kabalin M. Ferrari Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Antiandrogen treated patients J Urol 141 1989 1088
87. T.A. Stamey J.N. Kabalin J.E. McNeal Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients J Urol 141 1989 1076
88. C.A. Stein Suramin: A novel antineoplastic agent with multiple potential mechanisms of action Cancer Res 53 1993 2239
89. C.A. Stein R. LaRocca R.T. McAtee Suramin: An anticancer drug with a unique mechanism of action J Clin Oncol 7 1989 499
90. W. Sullivan T. Guthrie T. Gaddis Gallium nitrate (GN) and doxorubicin (DOX) therapy of hormone refractory prostate cancer (HRPC): Effects on parameters of pain, performance status (PS) and prostate specific antigen (PSA) [abstract 786] Proc Am Soc Clin Oncol 1993 250
91. W. Sullivan T. Guthrie T. Gaddis Gallium nitrate and doxorubicin therapy of hormone refractory prostate cancer [abstract 786] Proc Am Soc Clin Oncol 1993 250
92. S. Takeuchi I. Fukui Y. Higashi Combination chemotherapy with ifosphamide 5-fluorouracil, cisplatin for stage D2 prostate cancer. Hinyokika Kiyo Acta Urol Jpn 35 1989 1513
93. I. Tannock D. Osoba S. Ernst Chemotherapy with mitoxantrone (M) and prednisone (P) palliates patients with hormone-resistant prostate cancer (HRPC) Proc Am Soc Clin Oncol 1995 245
94. C.D. Taylor P. Elson D.I. Trump Importance of continued testicular suppression in hormone-refractory prostate cancer J Clin Oncol 11 1993 2167
95. F. Torti D. Aston B.L. Lum Weekly doxorubicin in endocrine refractory carcinoma of the prostate J Clin Oncol 1 1983 477
96. D.L. Trump J.C. Marsh L.K. Kvois A phase II trial of carbonation (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Group Pilot Study Invest New Drugs 8 1990 591
97. R.E. Van-Rijswijk E. Cvitkovic J. Wagstaff Workshop on suramin with emphasis on prostate cancer: Re-evaluation of response criteria Eur J Cancer 29A 1993 298
98. A. Veronesi V. Dal-Bo G. Lo-Re Mitomycin C treatment of advanced hormoneresistant prostatic carcinoma: A phase II study Cancer Chemother Pharmacol 23 1989 115
99. R. von Roemeling H.A.G. Fisher J. Horton Daily oral cyclophosphamide is effective in hormone refractory prostate cancer: A phase I/II study Proc Am Soc Clin Oncol 11 1992 213
100. P.J. Walther T.E. Keane A.N. Walker Treatment of metastatic hormone-refractory prostate carcinoma with cisplatin and continuous infusion 5-FU Proc Am Soc Clin Oncol 9 1990 308
101. K.S. Weiss A phase II study of recombinant leukocyte A human interferon intron-A (INT-A) in patients with hormone-refractory metastatic prostate cancer [abstract 738] Proc Am Soc Clin Oncol 1994 238
102. L.T. Williams P.M. Tremble M.F. Lavin Platelet-derived growth factor receptors form a high affinity state in membrane preparations: Kinetics and affinity crosslinking studies J Biol Chem 59 1984 5287
103. P.J. Woll M. Ranson J. Margison Suramin for breast and prostate cancer: A pilot study of intermittent short infusions without adaptive control Ann Oncol 5 1994 597
104. A. Yagoda D. Petrylak Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer Cancer 71 1993 1098 1109
105. A. Yagoda J.A. Smith M.D. Soloway Phase II study of estramustine phosphate in advanced hormone-refractory prostate cancer with increasing prostate specific antigen levels. [abstract 686] Proc Am Urol Assoc 1991 384